Trial Profile
A Phase II Study of RFS 2000 (9-Nitro-Camptothecin) in recurrent metastatic breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2014
Price :
$35
*
At a glance
- Drugs Rubitecan (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 26 Sep 2014 New trial record